A radiation oncology coder or compliance officer is reviewing 2026 CMS and AMA updates affecting treatment planning codes, IMRT billing, and technical versus professional component splits. They want to ensure past claims align with that year’s published guidance.
Great question to raise here. These 2026 changes are probably the most significant shake-up to radiation oncology billing in over a decade, so getting ahead of retrospective claim reviews is smart.
The headline change is the delivery code restructure. All external beam treatment delivery codes were consolidated into three complexity-based tiers: 77402 (Level 1), 77407 (Level 2), and 77412 (Level 3), effective January 1, 2026. The key philosophical shift here is that these new codes no longer distinguish strictly between 3D and IMRT, complexity of delivery is now the determining factor, such as use of multiple isocenters or active motion management.
On IMRT specifically: 77385 and 77386 were deleted, with IMRT folded into the three consolidated delivery levels. This is the one causing the most friction in retrospective reviews because coders who were previously billing 77385/77386 for IMRT need to map those claims carefully to the correct complexity tier.
For image guidance, the TC/PC split changed significantly. The technical component of image guidance is now bundled into the new delivery codes, so it can no longer be billed separately. The professional component has been consolidated into a single code, 77387. 77014 (CT guidance for placement of radiation therapy fields) was also deleted as a result of the TC bundling.
One practical compliance headache to flag: over 90% of survey respondents identified challenges around Level 3 delivery (77412), with payers frequently reclassifying high-complexity cases to lower tiers. If you’re auditing past claims, expect to document complexity indicators thoroughly, multiple isocenters, motion management, mixed modalities to defend 77412 assignments.
SRS and SBRT treatment planning and management codes were not substantially altered for 2026, so those should be lower risk for retrospective review.
For prior auth alignment, UHC updated its prior authorization requirements to reflect the new CPT codes starting January 1, 2026, and confirmed that authorizations approved under the old IMRT/IGRT codes for treatments beginning before that date did not require new requests. Worth checking your other major payers for similar transition language if you’re reconciling claims that span the cutover.
Happy to dig into specific mapping scenarios if anyone’s working through a particular claim set.
Solid breakdown from Samuel. The angle I’d add, specifically for retrospective review:
Your biggest exposure usually isn’t the IMRT remapping everyone’s focused on. It’s the payer adoption timeline mismatch. Medicare flipped on 1/1/2026, but commercial payers staggered their effective dates and transition policies. If you audit every pre-cutover claim against “2026 guidance,” you’ll generate false positives. Build a payer-by-payer effective-date matrix first, then test each claim against the rules that were actually live for that date of service.
Second, reframe what you’re auditing for. Since delivery is now technique-agnostic, the question shifts from “did we pick the right code” to “can our documentation defend the complexity tier we billed.” A 77412 claim without documented active motion management or multiple isocenters is your real recoupment risk, not a miscoded 3D case.
Last thing worth surfacing: ASTRO’s national survey found many practices seeing revenue drops of 10% or more even though CMS projected a roughly neutral impact, and the gap traces to how payers process the codes rather than the codes themselves. So run a paid-versus-expected variance report by payer alongside the compliance audit. Coding accuracy and revenue leakage are two different problems hiding behind the same code set.